Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.

Expert opinion on drug metabolism & toxicology - 1 Sept 2017

Berinstein Elliot, Levy Andrew

Abstract excerpt

INTRODUCTION: Cardiovascular disease is still the leading cause of death worldwide. There are many environmental and genetic factors that play a role in the development of cardiovascular disease. The treatment of cardiovascular disease is beginning to move in the direction of personalized medicine by using biomarkers from the patient's genome to design more effective treatment plans. Pharmacogenomics have already...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Agents
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ADRB1 gene

Share to PTGS2 gene

Share to Genetic Variation

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Precision Medicine

Source

Identifiers

PMID: 28792790
DOI: 10.1080/17425255.2017.1363887

Genes

ABCB1
ADCY9
ADRB1
CES1
PEAR1
PON1
PTGS1
PTGS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.PMID 28792790Read ↗

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Semantic proximity Read ↗

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Semantic proximity Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

Genetic determinants of response to cardiovascular drugs.Semantic proximity Read ↗

Use of pharmacogenomics in elderly patients treated for cardiovascular diseasesSemantic proximity Read ↗

Expanding Role of Pharmacogenomics in the Management of Cardiovascular DisordersSemantic proximity Read ↗

Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.Semantic proximity Read ↗

Pharmacogenomics in cardiovascular diseases.Semantic proximity Read ↗

Pharmacogenomics of drugs affecting the cardiovascular system.Semantic proximity Read ↗

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatmentSemantic proximity Read ↗

Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.Semantic proximity Read ↗

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.